Inhibikase Therapeutics, Inc. 8-K

What Happened On July 14, 2026, Inhibikase Therapeutics, Inc. announced via press release that it has made sales under its at‑the‑market (ATM) facility. The company filed a Current Report on Form 8‑K (Item 8.01) to disclose the press release, which is included as Exhibit 99.1 to the filing. The Form 8‑K does not itself disclose dollar amounts or share counts for the sales.

Key Details

• Filing date: July 14, 2026 (Form 8‑K, Item 8.01).
• Disclosure: Press release regarding ATM sales attached as Exhibit 99.1.
• The 8‑K notes sales were made under the company’s at‑the‑market facility; no amounts or share quantities are provided in the 8‑K.
• Exhibit list includes the press release and the Inline XBRL cover page (Exhibit 104).

Why It Matters An ATM sales update is a notice that the company has been raising capital by selling shares into the open market. For investors, ATM sales can increase the number of shares outstanding and affect supply/liquidity, which may influence the stock price. Because the 8‑K does not provide transaction amounts or share quantities, investors should review the attached press release and any subsequent filings for full details on the size and terms of the capital raised.